AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18343739 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy and/or crossover between first-line treatment arms
Number of subjects: 0
Study 18343739 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 0
Study 16911696 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose vitamin K3 (n = 23); administered by i.v. infusion of 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by 20 mg i.m. twice daily for 2 weeks
Number of subjects: 42
Study 16911696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 42
Study 12726869 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP intervention (exercise counseling and prescription of an exercise training heart rate)
Number of subjects: 284
Study 12726869 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP intervention
Number of subjects: 284
Study 12726869 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 284
Study 10985895 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC (100 mg/m² of cisplatin, 300 mg/m² of cyclophosphamide, 300 mg/m² of carboplatin)
Number of subjects: 195
Study 10985895 — intervention group
Group type: COMPARATOR
Intervention: CC (100 mg/m² of cisplatin, 600 mg/m² of cyclophosphamide)
Number of subjects: 195
Study 10985895 — intervention group
Group type: EXPERIMENTAL
Intervention: CCC
Number of subjects: 195
Study 9229324 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour bimonthly LV5-FU bolus and infusion
Number of subjects: 5
Study 9229324 — intervention group
Group type: COMPARATOR
Intervention: Control arm of ongoing trials
Number of subjects: 5
Study 1365656 — intervention group
Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 16
Study 1365656 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 16
Study 6738143 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly feedback of individual performance ranked with that of peers (group 1)
Number of subjects: 0
Study 6738143 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 0
Study 6738143 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2) receiving feedback in the second 6-month period
Number of subjects: 0
Study 6738143 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (no feedback in the second 6-month period)
Number of subjects: 0
Study 31276605 — intervention group
Group type: EXPERIMENTAL
Intervention: WWW-roadmap
Number of subjects: 128
Study 31276605 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual
Number of subjects: 128
Study 29246755 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 2251
Study 29246755 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age group (9.9-13 years)
Number of subjects: 2251
Study 29246755 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark skin complexion
Number of subjects: 2251
Study 26987997 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol Spiromax 160/4.5 mcg
Number of subjects: 574
Study 26987997 — intervention group
Group type: COMPARATOR
Intervention: Budesonide-formoterol Turbuhaler 200/6 mcg
Number of subjects: 574
Study 26987997 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol Spiromax
Number of subjects: 574
Study 26987997 — intervention group
Group type: COMPARATOR
Intervention: Budesonide-formoterol Turbuhaler
Number of subjects: 574
Study 24875654 — intervention group
Group type: EXPERIMENTAL
Intervention: TIP3-2 combined with medication (1-2 mg Estazolam nightly)
Number of subjects: 90
Study 24875654 — intervention group
Group type: COMPARATOR
Intervention: Medication only (1-2 mg Estazolam nightly)
Number of subjects: 90
Study 22367659 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertindole 16 mg
Number of subjects: 0
Study 22367659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20175658 — intervention group
Group type: EXPERIMENTAL
Intervention: Early full weight bearing protocol
Number of subjects: 14
Study 20175658 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation protocol (full weight bearing after 6 weeks)
Number of subjects: 14
Study 18172414 — intervention group
Group type: EXPERIMENTAL
Intervention: Tango classes
Number of subjects: 19
Study 18172414 — intervention group
Group type: COMPARATOR
Intervention: Exercise classes
Number of subjects: 19
Study 15738315 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapies for methamphetamine abuse
Number of subjects: 162
Study 12518253 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart, 0.05 U/kg-body-weight
Number of subjects: 20
Study 12518253 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro, 0.05 U/kg-body-weight
Number of subjects: 20
Study 9689296 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% aqueous sodium lauryl sulfate solution
Number of subjects: 17
Study 9689296 — intervention group
Group type: COMPARATOR
Intervention: Water‐ and untreated skin
Number of subjects: 17
Study 8135026 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal gentamicin (40 mg, 4 times a day)
Number of subjects: 67
Study 8135026 — intervention group
Group type: COMPARATOR
Intervention: Control (5% dextrose, 4 times a day)
Number of subjects: 67
Study 2758972 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital 50 mg
Number of subjects: 60
Study 2758972 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital 100 mg
Number of subjects: 60
Study 2758972 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital 200 mg
Number of subjects: 60
Study 2758972 — intervention group
Group type: EXPERIMENTAL
Intervention: Secobarbital (all doses)
Number of subjects: 60
Study 2758972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1102569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiapine (maximum dose of 450 mg per day)
Number of subjects: 60
Study 1102569 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (maximum daily dose of 900 mg)
Number of subjects: 60
Study 1102569 — intervention group
Group type: EXPERIMENTAL
Intervention: Metiapine
Number of subjects: 60
Study 1102569 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 60
Study 31721790 — intervention group
Group type: EXPERIMENTAL
Intervention: UB0316 (5 billion CFU each of L. salivarius UBLS22, L. casei UBLC42, L. plantarum UBLP40, L. acidophilus UBLA34, B. breve UBBr01, B. coagulans Unique IS2, and 100 mg fructo-oligosaccharides), twice-a-day for 12 weeks
Number of subjects: 79
Study 31721790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 28877858 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal turbinectomy with lateralization
Number of subjects: 109
Study 28877858 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal electrocautery
Number of subjects: 109
Study 28877858 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser cautery
Number of subjects: 109
Study 25144793 — intervention group
Group type: EXPERIMENTAL
Intervention: nevirapine-based ART
Number of subjects: 99
Study 25144793 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir-based ART
Number of subjects: 99
Study 25144793 — intervention group
Group type: EXPERIMENTAL
Intervention: lower 6-month gain in CD4%
Number of subjects: 99
Study 25144793 — intervention group
Group type: EXPERIMENTAL
Intervention: lower 6-month gains in weight-for-age
Number of subjects: 99
Study 25144793 — intervention group
Group type: EXPERIMENTAL
Intervention: lower 6-month gains in height-for-age
Number of subjects: 99
Study 25144793 — intervention group
Group type: EXPERIMENTAL
Intervention: lower 6-month gains in weight-for-height
Number of subjects: 99
Study 23499069 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue 0.1% injection (0.2 mL)
Number of subjects: 300
Study 23499069 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution injection (0.2 mL)
Number of subjects: 300
Study 23499069 — intervention group
Group type: EXPERIMENTAL
Intervention: Trypan blue group
Number of subjects: 300
Study 23499069 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 22368359 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous subepithelial connective tissue graft (SCTG)
Number of subjects: 10
Study 22368359 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable collagen membrane (GTRC)
Number of subjects: 10
Study 19877219 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab, mycophenolate mofetil, and tacrolimus (modified therapy group)
Number of subjects: 157
Study 19877219 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and steroids (standard therapy group)
Number of subjects: 157
Study 17076857 — intervention group
Group type: EXPERIMENTAL
Intervention: Amicus (A)
Number of subjects: 60
Study 17076857 — intervention group
Group type: COMPARATOR
Intervention: Trima (T)
Number of subjects: 60
Study 12679389 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG washout in patients with TPM1‐Asp175Asn
Number of subjects: 30
Study 12679389 — intervention group
Group type: EXPERIMENTAL
Intervention: (123)I‐MIBG washout in LV segments
Number of subjects: 30
Study 10735789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.94 mg/mL
Number of subjects: 100
Study 10735789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 1.88 mg/mL
Number of subjects: 100
Study 10735789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 2.83 mg/mL
Number of subjects: 100
Study 10735789 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (9.4 mg/mL) with ketamine (0.94-1.88 mg/mL)
Number of subjects: 100
Study 10735789 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 100
Study 8795320 — intervention group
Group type: EXPERIMENTAL
Intervention: Single orifice catheters
Number of subjects: 20
Study 8795320 — intervention group
Group type: COMPARATOR
Intervention: Multi-orifice catheters
Number of subjects: 20
Study 1412652 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (4 doses at 6-monthly intervals)
Number of subjects: 0
Study 1412652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2863777 — intervention group
Group type: EXPERIMENTAL
Intervention: Milenperone (2 X 5 mg daily for the first 3 weeks, then 2 X 10 mg daily for the following 3 weeks)
Number of subjects: 20
Study 2863777 — intervention group
Group type: EXPERIMENTAL
Intervention: Milenperone (2 X 10 mg daily)
Number of subjects: 20
Study 2863777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2863777 — intervention group
Group type: EXPERIMENTAL
Intervention: Milenperone
Number of subjects: 20
Study 30765235 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional circumferential supracrestal fiberotomy (CSF)
Number of subjects: 46
Study 30765235 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser‐aided circumferential supracrestal fiberotomy (CSF)
Number of subjects: 46
Study 30765235 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 46
Study 30765235 — intervention group
Group type: EXPERIMENTAL
Intervention: Probing depth
Number of subjects: 46
Study 30765235 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical crown height
Number of subjects: 46
Study 30765235 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain levels
Number of subjects: 46
Study 25477057 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by ultrasonography (US) feedback
Number of subjects: 95
Study 25477057 — intervention group
Group type: COMPARATOR
Intervention: Standard care without education
Number of subjects: 95
Study 25558638 — intervention group
Group type: EXPERIMENTAL
Intervention: McGrath Series 5 video laryngoscope
Number of subjects: 80
Study 25558638 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 80
Study 22479542 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Ad5 HIV-1 gag vaccine
Number of subjects: 104
Study 19375704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (50 microg, 4-hourly, up to 3 doses)
Number of subjects: 61
Study 19375704 — intervention group
Group type: COMPARATOR
Intervention: Intracervical PGE2 gel (2 applications at 6-hour interval)
Number of subjects: 61
Study 19375704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol
Number of subjects: 61
Study 19375704 — intervention group
Group type: COMPARATOR
Intervention: Intracervical PGE2 gel
Number of subjects: 61
Study 17487535 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week pulmonary rehabilitation program (exercise plus education)
Number of subjects: 54
Study 17487535 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 15247492 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-step PCR assay for quantification of Epstein-Barr virus (EBV) DNA in peripheral blood.
Number of subjects: 0
Study 15247492 — intervention group
Group type: EXPERIMENTAL
Intervention: Semiquantitative PCR assay followed by quantitative-competitive (QC)-PCR assay.
Number of subjects: 0
Study 11290990 — intervention group
Group type: EXPERIMENTAL
Intervention: Soothing music and low noise levels in the PACU (experimental group)
Number of subjects: 97
Study 11290990 — intervention group
Group type: COMPARATOR
Intervention: Typical PACU environment (control group)
Number of subjects: 97
Study 9569434 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin
Number of subjects: 70
Study 9569434 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 70
Study 9569434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 8626081 — intervention group
Group type: EXPERIMENTAL
Intervention: SLO perimetry
Number of subjects: 50
Study 8626081 — intervention group
Group type: COMPARATOR
Intervention: Octopus 500 (program 38)
Number of subjects: 50
Study 8626081 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SLO and Octopus
Number of subjects: 50
Study 2666736 — intervention group
Group type: EXPERIMENTAL
Intervention: cordiamine
Number of subjects: 48
Study 2666736 — intervention group
Group type: EXPERIMENTAL
Intervention: phenobarbital
Number of subjects: 48
Study 2666736 — intervention group
Group type: EXPERIMENTAL
Intervention: ziscorine
Number of subjects: 48
Study 2666736 — intervention group
Group type: EXPERIMENTAL
Intervention: phenobarbital and pyrogenal combination
Number of subjects: 48
Study 785959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (3 to 1.5 mg/kg b.wt. for 4 months)
Number of subjects: 50
Study 785959 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 50
Study 31646339 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise (n = 38)
Number of subjects: 54
Study 31646339 — intervention group
Group type: COMPARATOR
Intervention: Wait-list usual care (n = 18)
Number of subjects: 54
Study 31255386 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with LPE treated before day 6
Number of subjects: 137
Study 31255386 — intervention group
Group type: COMPARATOR
Intervention: Enrolled infants in the PDA-TOLERATE trial
Number of subjects: 137
Study 28632467 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) combined with functional training
Number of subjects: 20
Study 28632467 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study 26202439 — intervention group
Group type: EXPERIMENTAL
Intervention: New Nordic Diet (NND) school meals
Number of subjects: 834
Study 26202439 — intervention group
Group type: COMPARATOR
Intervention: Usual packed lunches (control)
Number of subjects: 834
Study 23536769 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER)
Number of subjects: 14
Study 23536769 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (COMB)
Number of subjects: 14
Study 21610429 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachioradialis rSO2 measurements in ICU septic shock patients
Number of subjects: 19
Study 21610429 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate concentration in ICU septic shock patients
Number of subjects: 19
Study 21610429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac index in ICU septic shock patients
Number of subjects: 19
Study 20137542 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg/day)
Number of subjects: 102
Study 20137542 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 102
Study 20137542 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (80 mg/day)
Number of subjects: 102
Study 16621226 — intervention group
Group type: COMPARATOR
Intervention: Hydralazine (5 mg as a slow bolus dose given intravenously, repeated every 20 min up to a maximum of five doses)
Number of subjects: 200
Study 16621226 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (20‐mg intravenous bolus dose followed by 40 mg if not effective within 20 min, followed by 80 mg every 20 min up to a maximum dose of 300 mg)
Number of subjects: 200
Study 15137563 — intervention group
Group type: EXPERIMENTAL
Intervention: Seating Identification Tool (SIT)
Number of subjects: 42
Study 15137563 — intervention group
Group type: COMPARATOR
Intervention: Formal evaluation by a therapist
Number of subjects: 42
Study 11375358 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol plus Metformin
Number of subjects: 324
Study 11375358 — intervention group
Group type: COMPARATOR
Intervention: Metformin alone
Number of subjects: 324
Study 9423902 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids (fluorometholone 0.1%)
Number of subjects: 0
Study 9423902 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 0.1% (Decrol)
Number of subjects: 0
Study 9423902 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen sodium 0.03% (Ocufen)
Number of subjects: 0
Study 9423902 — intervention group
Group type: COMPARATOR
Intervention: NSAID subgroups (Flurbiprofen and Diclofenac)
Number of subjects: 0
Study 8274583 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine infusion
Number of subjects: 29
Study 8274583 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion (Control)
Number of subjects: 29
Study 6134093 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth chair
Number of subjects: 189
Study 6134093 — intervention group
Group type: COMPARATOR
Intervention: Conventional dorsal position
Number of subjects: 189
Study 30697688 — intervention group
Group type: COMPARATOR
Intervention: Low volume interscalene block using 5 mL of ropivacaine 0.5% (LVS group)
Number of subjects: 72
Study 30697688 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular-subomohyoid block using 25 mL of ropivacaine 0.5% (ISO group)
Number of subjects: 72
Study 30697688 — intervention group
Group type: COMPARATOR
Intervention: Low volume interscalene block (LVS group)
Number of subjects: 72
Study 30697688 — intervention group
Group type: EXPERIMENTAL
Intervention: Infraclavicular-subomohyoid block (ISO group)
Number of subjects: 72
Study 28376674 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (WBVT) for 6 weeks, 3 sessions per week
Number of subjects: 33
Study 28376674 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 33
Study 26895715 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital fast track care (PFTC)
Number of subjects: 400
Study 26895715 — intervention group
Group type: COMPARATOR
Intervention: Traditional care pathway (A&E group)
Number of subjects: 400
Study 25571679 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP‐ACP cream (Tooth Mousse, GC Europe N.V., Leuven, Belgium)
Number of subjects: 60
Study 25571679 — intervention group
Group type: COMPARATOR
Intervention: Fluoride containing toothpaste
Number of subjects: 60
Study 25571679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CPP‐ACP and control)
Number of subjects: 60
Study 22698005 — intervention group
Group type: EXPERIMENTAL
Intervention: Retroperitoneal laparoscopic radical nephrectomy (n=31)
Number of subjects: 62
Study 22698005 — intervention group
Group type: COMPARATOR
Intervention: Open radical nephrectomy (n=31)
Number of subjects: 62
Study 22698005 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 19328538 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg daily
Number of subjects: 18882
Study 19328538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18882
Study 17327342 — intervention group
Group type: EXPERIMENTAL
Intervention: NOS3 ‐786T‐‐>C genotype
Number of subjects: 36
Study 17327342 — intervention group
Group type: EXPERIMENTAL
Intervention: Glu298Glu genotype
Number of subjects: 36
Study 17327342 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate analysis including age, sex, BMI percentile, and ‐786T‐‐>C genotype
Number of subjects: 36
Study 17327342 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate model including age, sex, BMI percentile, and ‐786T‐‐>C genotype
Number of subjects: 36
Study 16469616 — intervention group
Group type: EXPERIMENTAL
Intervention: Microsurgical approach using isosulfan blue
Number of subjects: 50
Study 16469616 — intervention group
Group type: COMPARATOR
Intervention: Standard microsurgery
Number of subjects: 50
Study 15467218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sho-hange-ka-bukuryo-to
Number of subjects: 0
Study 15467218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10391259 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministernotomy (group M)
Number of subjects: 40
Study 10391259 — intervention group
Group type: COMPARATOR
Intervention: Median sternotomy (group S)
Number of subjects: 40
Study 8913975 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 67
Study 8913975 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactated Ringer's solution
Number of subjects: 67
Study 1678760 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% chlorhexidine (CHX)
Number of subjects: 56
Study 1678760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 6837786 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral ECT (N = 24)
Number of subjects: 51
Study 6837786 — intervention group
Group type: COMPARATOR
Intervention: Unilateral ECT (N = 27)
Number of subjects: 51